The second bellwether trial against Sanofi-Aventis over its prescription chemotherapy drug Taxotere began today.

The trial in New Orleans is one of nearly 12,500 lawsuits coordinated in multidistrict litigation alleging that women who take Taxotere, a chemotherapy drug used to treat breast cancer, never grow back their hair, a side effect the U.S. Food and Drug Administration acknowledged in a labeling change in 2015. The first bellwether trial ended in a defense verdict in 2019.